Document is current
Any future updates will be listed below
-
Authors
Szklarzewicz, Justyna
Floege, Ute
Gallego, Daniel
Gibson, Keisha
Kalantar-Zadeh, Kamyar
Helm, Kelly
Robinson, Dale
Schneider, Bonnie
Smith, Philip
Tullus, Kjell
Poyan-Mehr, Ali
Hendry, Bruce
Balkaran, Bridget L.
Jauregui, Adam K.
Wang, Aolin
Nason, Ian
Hazra, Nisha C.
Xu, Chunyi
Liu, Jingyi
Zhou, Zheng-Yi
Bensink, Mark https://orcid.org/0000-0002-5940-7898
-
Funding
Funding for this research was provided by:
Travere Therapeutics, Inc. (Travere Therapeutics, Inc.)
- License Information
-
More Information
Article History
Accepted: 11 October 2024
First Online: 26 October 2024
Declarations
:
: The survey and all associated patient-facing materials were granted an exemption from full review by the Pearl Institutional Review Board on June 21, 2021, and the study is compliant with the Health Insurance Portability and Accountability Act and Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.
: Bruce Hendry is an employee of Travere Therapeutics, Inc. and holds stock/options. Mark Bensink is Managing Director of Benofit Consulting, which received consulting fees from Travere Therapeutics, Inc. for this work. Justyna Szklarzewicz, Ute Floege, Daniel Gallego, Keisha Gibson, Kamyar Kalantar-Zadeh, Kelly Helm, Dale Robinson, Bonnie Schneider, Philip Smith, Kjell Tullus, and Ali Poyan-Mehr received consultancy fees from Travere Therapeutics, Inc. for this work. Bridget L Balkaran and Adam K Jauregui are employees of Oracle Life Sciences, which received consultancy fees from Travere Therapeutics, Inc. for this work. Jingyi Liu, Chunyi Xu, Ian Nason, Aolin Wang, Nisha C. Hazra and Zheng-Yi Zhou are employees of Analysis Group, which received consultancy fees from Travere Therapeutics, Inc. for this work.
